168 related articles for article (PubMed ID: 18620776)
1. Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion.
Fujita N; Sugimoto R; Motonishi S; Tomosugi N; Tanaka H; Takeo M; Iwasa M; Kobayashi Y; Hayashi H; Kaito M; Takei Y
J Hepatol; 2008 Nov; 49(5):702-10. PubMed ID: 18620776
[TBL] [Abstract][Full Text] [Related]
2. Hepcidin/ferroportin expression levels involve efficacy of pegylated-interferon plus ribavirin in hepatitis C virus-infected liver.
Kohjima M; Yoshimoto T; Enjoji M; Fukushima N; Fukuizumi K; Nakamura T; Kurokawa M; Fujimori N; Sasaki Y; Shimonaka Y; Murata Y; Koyama S; Kawabe K; Haraguchi K; Sumida Y; Harada N; Kato M; Kotoh K; Nakamuta M
World J Gastroenterol; 2015 Mar; 21(11):3291-9. PubMed ID: 25805936
[TBL] [Abstract][Full Text] [Related]
3. Low hepcidin triggers hepatic iron accumulation in patients with hepatitis C.
Hörl WH; Schmidt A
Nephrol Dial Transplant; 2014 Jun; 29(6):1141-4. PubMed ID: 24286977
[TBL] [Abstract][Full Text] [Related]
4. Hepatic iron influences responses to combination therapy with peginterferon alfa and ribavirin in chronic hepatitis C.
Lin TJ; Liao LY; Lin CL; Chang TA; Liu SO
Hepatogastroenterology; 2008; 55(85):1412-5. PubMed ID: 18795701
[TBL] [Abstract][Full Text] [Related]
5. Pegylated interferon-α induced hypoferremia is associated with the immediate response to treatment in hepatitis C.
Ryan JD; Altamura S; Devitt E; Mullins S; Lawless MW; Muckenthaler MU; Crowe J
Hepatology; 2012 Aug; 56(2):492-500. PubMed ID: 22334511
[TBL] [Abstract][Full Text] [Related]
6. Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C.
Fujita N; Sugimoto R; Urawa N; Araki J; Mifuji R; Yamamoto M; Horiike S; Tanaka H; Iwasa M; Kobayashi Y; Adachi Y; Kaito M
J Gastroenterol Hepatol; 2007 Nov; 22(11):1886-93. PubMed ID: 17914965
[TBL] [Abstract][Full Text] [Related]
7. Hepcidin levels and iron status in beta-thalassemia major patients with hepatitis C virus infection.
Hendy OM; Allam M; Allam A; Attia MH; El Taher S; Eldin MM; Ali A
Egypt J Immunol; 2010; 17(2):33-44. PubMed ID: 23082485
[TBL] [Abstract][Full Text] [Related]
8. The role of iron overload and HFE gene mutations in the era of pegylated interferon and ribavirin treatment of chronic hepatitis C.
Sikorska K; Stalke P; Izycka-Swieszewska E; Romanowski T; Bielawski KP
Med Sci Monit; 2010 Mar; 16(3):CR137-143. PubMed ID: 20190684
[TBL] [Abstract][Full Text] [Related]
9. Reduced serum hepcidin levels in patients with chronic hepatitis C.
Girelli D; Pasino M; Goodnough JB; Nemeth E; Guido M; Castagna A; Busti F; Campostrini N; Martinelli N; Vantini I; Corrocher R; Ganz T; Fattovich G
J Hepatol; 2009 Nov; 51(5):845-52. PubMed ID: 19729219
[TBL] [Abstract][Full Text] [Related]
10. New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.
Abe H; Aida Y; Ishiguro H; Yoshizawa K; Seki N; Miyazaki T; Itagaki M; Sutoh S; Ika M; Kato K; Shimada N; Tsubota A; Aizawa Y
J Med Virol; 2013 Sep; 85(9):1523-33. PubMed ID: 23775277
[TBL] [Abstract][Full Text] [Related]
11. Changes in the Serum Hepcidin-to-ferritin Ratio with Erythroferrone after Hepatitis C Virus Eradication Using Direct-acting Antiviral Agents.
Inomata S; Anan A; Yamauchi E; Yamauchi R; Kunimoto H; Takata K; Tanaka T; Yokoyama K; Morihara D; Takeyama Y; Irie M; Shakado S; Sohda T; Sakisaka S
Intern Med; 2019 Oct; 58(20):2915-2922. PubMed ID: 31243222
[TBL] [Abstract][Full Text] [Related]
12. Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C.
Fujita N; Sugimoto R; Takeo M; Urawa N; Mifuji R; Tanaka H; Kobayashi Y; Iwasa M; Watanabe S; Adachi Y; Kaito M
Mol Med; 2007; 13(1-2):97-104. PubMed ID: 17515961
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
Sullivan SD; Jensen DM; Bernstein DE; Hassanein TI; Foster GR; Lee SS; Cheinquer H; Craxi A; Cooksley G; Klaskala W; Pettit K; Patel KK; Green J
Am J Gastroenterol; 2004 Aug; 99(8):1490-6. PubMed ID: 15307866
[TBL] [Abstract][Full Text] [Related]
14. Hepatic oxidative DNA damage correlates with iron overload in chronic hepatitis C patients.
Fujita N; Horiike S; Sugimoto R; Tanaka H; Iwasa M; Kobayashi Y; Hasegawa K; Ma N; Kawanishi S; Adachi Y; Kaito M
Free Radic Biol Med; 2007 Feb; 42(3):353-62. PubMed ID: 17210448
[TBL] [Abstract][Full Text] [Related]
15. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
[TBL] [Abstract][Full Text] [Related]
16. Association of hepatic oxidative stress and iron dysregulation with HCC development after interferon therapy in chronic hepatitis C.
Nanba S; Ikeda F; Baba N; Takaguchi K; Senoh T; Nagano T; Seki H; Takeuchi Y; Moritou Y; Yasunaka T; Ohnishi H; Miyake Y; Takaki A; Nouso K; Iwasaki Y; Yamamoto K
J Clin Pathol; 2016 Mar; 69(3):226-33. PubMed ID: 26290259
[TBL] [Abstract][Full Text] [Related]
17. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
[TBL] [Abstract][Full Text] [Related]
18. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.
Lee SD; Yu ML; Cheng PN; Lai MY; Chao YC; Hwang SJ; Chang WY; Chang TT; Hsieh TY; Liu CJ; Chen DS
J Viral Hepat; 2005 May; 12(3):283-91. PubMed ID: 15850469
[TBL] [Abstract][Full Text] [Related]
19. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination.
Dumortier J; Scoazec JY; Chevallier P; Boillot O
J Hepatol; 2004 Apr; 40(4):669-74. PubMed ID: 15030984
[TBL] [Abstract][Full Text] [Related]
20. [Virological response of chronic hepatitis C management with peg-interferon alpha-2b and ribavirin].
Ma XJ; Li ZR; Li DM; Fan YM; Liao GX; Li TS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Oct; 28(5):721-3. PubMed ID: 17121241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
